Newsroom
GlioCART receives CHF 150,000 from Venture Kick to fight the most aggressive form of brain cancer
17.11.2025
GlioCART has obtained CHF 150,000 from Venture Kick to develop a new type of cell therapy – the first CAR-T cell therapy – designe ... more
Forgis receives CHF 150,000 from Venture Kick to enable production reshoring through industrial intelligence
14.11.2025
ETH Zurich and HSG startup Forgis has obtained CHF 150,000 from Venture Kick to make factory automated systems intelligent. By int ... more
Virometix secures USD 15 million to advance novel pneumococcal vaccine
13.11.2025
Schlieren-based Virometix, a biotechnology company developing fully synthetic vaccines designed to generate targeted immune respon ... more
Media contacts
For media enquiries, please email our communications team. If you have a general question about Venture Kick please visit our about us page.
Learn more about Venture Kick or download the latest annual report for detailed information.
